Skip to main content
NCBI home page
Journal of Cerebral Blood Flow & Metabolism logoLink to Journal of Cerebral Blood Flow & Metabolism
. 2013 Dec 11;34(3):450–459. doi: 10.1038/jcbfm.2013.217

Immune cell infiltration in malignant middle cerebral artery infarction: comparison with transient cerebral ischemia

Hannah X Chu 1, Hyun Ah Kim 1, Seyoung Lee 1, Jeffrey P Moore 1, Christopher T Chan 1, Antony Vinh 1, Mathias Gelderblom 2, Thiruma V Arumugam 3, Brad RS Broughton 1, Grant R Drummond 1, Christopher G Sobey 1,*
PMCID: PMC3948121  PMID: 24326388

Abstract

We tested whether significant leukocyte infiltration occurs in a mouse model of permanent cerebral ischemia. C57BL6/J male mice underwent either permanent (3 or 24 hours) or transient (1 or 2 hours+22- to 23-hour reperfusion) middle cerebral artery occlusion (MCAO). Using flow cytometry, we observed ∼15,000 leukocytes (CD45+high cells) in the ischemic hemisphere as early as 3 hours after permanent MCAO (pMCAO), comprising ∼40% lymphoid cells and ∼60% myeloid cells. Neutrophils were the predominant cell type entering the brain, and were increased to ∼5,000 as early as 3 hours after pMCAO. Several cell types (monocytes, macrophages, B lymphocytes, CD8+ T lymphocytes, and natural killer cells) were also increased at 3 hours to levels sustained for 24 hours, whereas others (CD4+ T cells, natural killer T cells, and dendritic cells) were unchanged at 3 hours, but were increased by 24 hours after pMCAO. Immunohistochemical analysis revealed that leukocytes typically had entered and widely dispersed throughout the parenchyma of the infarct within 3 hours. Moreover, compared with pMCAO, there were ∼50% fewer infiltrating leukocytes at 24 hours after transient MCAO (tMCAO), independent of infarct size. Microglial cell numbers were bilaterally increased in both models. These findings indicate that a profound infiltration of inflammatory cells occurs in the brain early after focal ischemia, especially without reperfusion.

Keywords: immune cell infiltration, inflammation, leukocytes, malignant middle cerebral artery infarction, middle cerebral artery occlusion, stroke

Introduction

Stroke is a leading cause of death and disability worldwide, and accounts for ∼1 in every 18 deaths in the United States.1 Recanalization of occluded vessels with intravenously administered recombinant tissue plasminogen activator within 4.5 hours of onset of stroke symptoms is currently the only approved acute stroke treatment.2 However, the requirement for CT confirmation of an ischemic stroke together with the short therapeutic window limits its utility.

Approximately 10% to 15% of all ischemic brain infarcts affect large sections of one hemisphere, leading to ‘malignant' media infarctions—a decisive factor for early mortality.3, 4 ‘Malignant middle cerebral artery (MCA) infarction' describes a massive, space-occupying total or subtotal infarction in the territory of the MCA.4, 5 It is typically caused by an embolic occlusion of a distal internal carotid artery or proximal MCA segment. A very low recanalization rate (either spontaneous or therapeutic) of such occlusions results in ischemic lesions involving substantial parts of the affected MCA territory. Secondary to the initial damage, massive brain edema develops in the initial days after ischemia, leading to progressively elevated intracranial pressure. These events result in the involvement of formerly unaffected tissue and might even cause supratentorial herniation. In the subgroup of patients who develop malignant MCA infarction there is a mortality rate of 80%, compared with 5% to 45% in all patients with acute ischemic MCA territory stroke.4, 6 For treatment, decompressive hemicraniectomy surgery may be employed to normalize intracranial pressure and increase survival rate but it provides limited improvement in infarct volume and functional outcomes.7 Opportunities to identify new directions that may enable treatment of acute stroke, especially in severe cases in which reperfusion has not occurred, must therefore be explored as a matter of urgency.

There is now strong evidence that inflammatory processes may contribute to secondary brain damage after ischemic stroke, and that this involves numerous types of immune cells infiltrating the postischemic brain with varying numerical, temporal, and spatial profiles after reperfusion.8 These infiltrating cells include neutrophils, monocytes, macrophages, dendritic cells, T and B lymphocytes, and natural killer cells.8 For example, clinical and experimental data suggest that neutrophils are a key immune cell to enter the brain after ischemia, and neutrophil number correlates with the severity of an ischemic lesion,9, 10 although there is some controversy as to whether this is an early event or is delayed by up to 3 days.8 It is also remains controversial as to whether neutrophils contribute directly to secondary brain damage or are merely bystanders that mainly assist in promoting tissue repair and recovery.11, 12 Further, T lymphocytes are now understood to contribute to ischemic brain injury after reperfusion.13, 14 Thus, Rag1−/− mice that are deficient in lymphocytes appear to be partially protected from severe histochemical and functional outcomes after cerebral ischemia and reperfusion due to the absence of T lymphocytes.15 By contrast, other infiltrating cells such as regulatory B cells may act to limit severity of stroke outcome after transient cerebral ischemia.16 Hence, if the identities of culprit immune cell subpopulations and their time course of injury in specific stroke settings can be accurately determined, then it seems plausible that this information could be exploited to develop new interventional therapies to specifically block such effects within a rational therapeutic window of hours to days after stroke.

It is noteworthy that experimental assessment of inflammation and immune cell infiltration after stroke has typically been performed in models of cerebral ischemia with reperfusion. However, the involvement of such processes in brain injury occurring after severe permanent cerebral ischemia (i.e., ischemia with no reperfusion), such as in malignant MCA infarction, remains largely unknown. Indeed, it might be postulated that immune cell infiltration is minimal, or even absent, in the postischemic brain in the absence of reperfusion. Thus, here we have employed a flow cytometric approach to carefully assess the increases in multiple immune cell types in the postischemic mouse brain at an early (3 hours) and late (24 hours) time point in the first day after permanent MCA occlusion (pMCAO). We have compared those findings with the profile observed in other mice subjected to transient (1 hour) MCA occlusion (tMCAO) followed by 23-hour reperfusion. Our findings indicate that, despite the absence of reperfusion, immune cell infiltration occurs relatively quickly after the onset of ischemia, is sustained for at least 24 hours, and involves ∼2-fold more leukocytes than are present in the brain 24 hours after transient ischemia, independently of infarct size.

Materials and methods

Middle Cerebral Artery Occlusion

This study fully adheres to ARRIVE guidelines.17 All experiments were approved by Monash University Animal Ethics Committee (Project MARP/2011/112) and conducted according to National Health and Research Council Australia guidelines for the care and use of animals in research. Male C57Bl6/J mice (22 to 32 g, 8 to 12 weeks, n=101) underwent either sham surgery (n=40), pMCAO (n=40) or 1or 2 hours of tMCAO (n=13 and 8, respectively), as described previously.14 Briefly, mice were anesthetized with a mixture of ketamine (80 mg/kg) and xylazine (10 mg/kg), and body temperature was maintained at 37±0.5 °C throughout the surgery using a heat lamp. A midline incision was made, and connective tissue was teased away to expose the common carotid artery. After cauterizing a branch of the external carotid artery, the external carotid artery was ligated distal to the bifurcation of the common carotid artery. Focal ischemia was induced by occlusion of the right MCA with a nylon monofilament with silicone-coated tip (0.20 to 0.22 mm, Doccol Co., Redlands, CA, USA). Transcranial laser-Doppler flowmetry (Perimed, Jarfalla, Sweden) was used to confirm a severe reduction (>75%) in cerebral blood flow in the area of cerebral cortex supplied by the MCA. The filament was either tied in place permanently for pMCAO, or retracted after 1 hour of ischemia for tMCAO, allowing reperfusion to occur. Wounds were sutured and covered with betadine and spray dressing (Smith and Nephew, Hull, UK). Mice were monitored until they regained consciousness and were returned to their cages (specific pathogen free, room temperature=21 °C). Time-matched sham-operated control animals underwent all procedures except ligation of any arteries. Further, age-matched naïve animals (not subjected to surgery; n=24) were also included as controls.

Flow Cytometry

On each occasion when flow cytometry was utilized, we studied at least one poststroke mouse together with a time-matched sham-operated control mouse. Animals were euthanased at specified time points after ischemia (3or 24 hours after pMCAO; 24 hours after 1 or 2 hours of tMCAO) by isoflurane inhalation, followed by blood removal and decapitation. Brain, blood, and spleen were collected from each animal for flow cytometric analyses. Blood was collected by cardiac puncture and leukocytes were purified using red blood cell lysis buffer (155 mmol/L NH4Cl, 10 mmol/L KHCO3, and 3 μmol/L EDTA). Spleens were mechanically dissociated and passed through 70 μm nylon cell strainers (BD Falcon, Bedford, MA, USA) to obtain a single-cell suspension. Cells were then lysed with red blood cell lysis buffer and washed with phosphate-buffered saline (PBS) containing 1% bovine serum albumin.

The brain was removed from the skull and after removing the cerebellum, was separated into left (contralateral) and right (ischemic) hemispheres. In some experiments, brains were flushed with PBS before removal and cell counts were compared with those collected in parallel but without flushing (3-hour sham: n=4 each; 24-hour sham or 24-hour pMCAO: n=5 each). Each hemisphere was dissociated mechanically in digestion buffer containing collagenase type XI (125 U/mL), hyaluronidase (60 U/mL), and collagenase type I-S (450 U/mL) in Ca2+/Mg2+-supplemented PBS (Sigma, St Louis, MO, USA), and incubated at 37 °C for 30 minutes with gentle agitation. The mixture was then passed through 70 μm nylon cell strainers to obtain a single-cell suspension. After washing with PBS (1,200 r.p.m., 10 minutes), the cell pellet was resuspended in 3 mL 30% percoll (GE Healthcare, Uppsala, Sweden), underlaid with 70% percoll, and centrifuged for 20 minutes at 2,400 r.p.m. at room temperature without the use of a brake. The cells at the interphase of two density gradients were collected and washed with PBS containing 1% bovine serum albumin (1,200 r.p.m., 10 minutes) for staining. All cells were incubated with appropriate antibodies listed in Table 1 at 4 °C in darkness for 20 minutes. After staining, cells were analyzed by LSRII (BD Biosciences, Franklin Lakes, NJ, USA) and FlowJo software (Tree Star Inc., Ashland, OR, USA). Countbright counting beads (Invitrogen, Carlsbad, CA, USA) were included to define the absolute number of cells in the samples.

Table 1. Antibodies used for flow cytometry and immunohistochemistry.

Antigen Host/Isotype Clone Supplier
Flow cytometry
 CD8a Rat IgG2a, kappa 53-6.7 BD Phamingen
 B220 Rat IgG2a, kappa RA3-6B2 BioLegend
 CD11c ArHam IgG N418 BioLegend
 CD25 Rat IgG1, lambda PC61.5 BioLegend
 CD4 Rat IgG2b, kappa GK1.5 BioLegend
 CD45 Rat IgG2b, kappa 30-F11 BioLegend
 CD49b ArHam IgG HMα2 BioLegend
 CD90.2 Rat IgG2b, kappa 30-H12 BioLegend
 Ly6C Rat IgG2c, kappa HK1.4 BioLegend
 Ly6G Rat IgG2a, kappa 1A8 BioLegend
 NK1.1 Mouse IgG2a, kappa PK136 BioLegend
 CD11b Rat IgG2b, kappa M1/70 eBioscience
 CD3 Rat IgG2b, kappa 17A2 eBioscience
 F4/80 Rat IgG2a, kappa BM8 eBioscience
 7-Amino-actinomycin D (7AAD)     Invitrogen
 B220 Rat IgG2a RA3-6B2 Invitrogen
       
Immunohistochemistry
 CD3 Rabbit IgG SP7 Abcam
 Iba1 Goat IgG Polyclonal Abcam
 MPO Rabbit IgG Polyclonal Abcam
 von Willebrand factor Mouse IgG1 F8/80 Abcam
 Rabbit IgG Alexa Fluor 594 Goat IgG (H+L) Polyclonal Life Technologies
 Goat IgG Alexa Fluor 594 Rabbit IgG (H+L) Polyclonal Life Technologies
Open in a new tab

Gating Strategy

Single cells were identified by forward scatter, and dead cells (7AAD+) were excluded. Cells were gated for CD45+high and CD45+med populations. CD45+high populations (leukocytes) were then divided into lymphoid cells, which include: B cells (B220+), T cells (CD49b+CD90−NK1.1−), thymocytes (CD49b−CD90+NK1.1−), natural killer (NK) cells (CD49b+CD90+NK1.1+) and natural killer T (NKT) cells (CD49b+CD90−NK1.1+); and myeloid cells (CD11b+). CD45+medCD11b+F4/80+ cells were considered as microglia. Two panels of antibodies were used, one of which was employed with each animal. Panel 1 enabled the counting of microglia and myeloid-derived leukocytes (i.e., CD11b+ cells; Supplementary Figure 1A), which included: neutrophils (Ly6G+), monocytes (Ly6C+), macrophages (F4/80+), and dendritic cells (CD11c+); whereas panel 2 divided lymphocytes into B cells (B220+), T cells (CD3+), NKT cells (NK1.1+CD3+), and NK cells (NK1.1+). T cells were then further subdivided into CD4+ T cells, CD8+ T cells, CD4−CD8− T cells, and CD4+CD25+ T cells (Supplementary Figure 1B). Fluorescence-minus-one was included as negative controls to define positive populations for F4/80, CD11c, B220, CD3, and CD25.

Immunohistochemistry

Animals (n=4) were euthanased at 3 hours after pMCAO, brains were quickly removed, frozen in liquid nitrogen and stored at −80 °C. Brains were sectioned coronally at 10 μm using a cryostat. Thionin stain was performed in 30 μm adjacent sections according to standard protocol to identify infarct regions. Immunohistochemistry of myeloperoxidase (MPO; 1:1,000, Abcam, Cambridge, UK) was performed according to standard protocols of Dako Invision Plus kits (Dako, Glostrup, Denmark).11 In addition, sections were assessed for localization of leukocytes (neutrophils, T cells, and macrophages) in relation to blood vessels using costaining with vonWillebrand Factor and MPO, CD3, or F4/80, respectively. Microglia (Iba+ cells) number was also estimated manually from some sections. Staining was analyzed using an Olympus light microscope (Hamburg, Germany). Eight 1 mm2 areas were randomly selected from within each of four coronal sections of each brain in contralateral; noninfarct (ipsilateral); or infarct (1 mm within the infarct border and also >1 mm away from the infarct border) regions. The number of MPO+ cells was quantified in each 1 mm2 area and the densities of MPO+ cells from different regions were compared.

Statistical Analysis

All data were analyzed using GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA) and presented as mean±standard error (s.e.m.). Data for pMCAO from flow cytometry were analyzed using two-way analysis of variance (ANOVA) with Bonferroni post tests for multiple comparison of different times and treatments. Data for tMCAO from flow cytometry and immunohistochemical studies were analyzed using one-way ANOVA with Bonferroni post hoc test. A P value of <0.05 was considered as statistically significant.

Results

Characteristics of Mouse Models of Stroke

All mice subjected to pMCAO or tMCAO received ∼80% reduction in cerebral blood flow in the region supplied by the MCA, as assessed by laser-Doppler flowmetry (Supplementary Figure 2A to D). After tMCAO (i.e., 1 or 2 hours of MCAO), regional blood flow increased to the preischemia level within 30 minutes after withdrawal of the filament (Supplementary Figure 2C and D). Eight animals were excluded due to death before the predetermined time of euthanasia (i.e., 24 hours after pMCAO or tMCAO; see the following text for details). Mortality was: 0% (0/15) among mice in the 3-hour pMCAO group, 12% (3/25) in the 24-hour pMCAO group, 23% (3/13) in the 1-hour tMCAO group, and 25% (2/8) in the 2-hour tMCAO group. There were no mortalities among sham-operated control mice. In the surviving animals, pMCAO produced a large infarct throughout the cortex and the striatum, which was evident at 3 hours (Supplementary Figure 2E), and which occupied most of the ipsilateral hemisphere by 24 hours (Supplementary Figure 2F). By comparison, infarct volume was smaller and restricted mainly to the striatum at 23 hours after 1 hour of tMCAO (Supplementary Figure 2G), whereas 2-hour tMCAO plus 22-hour reperfusion produced an infarct that was comparable in size to the pMCAO groups.

Immune Cell Numbers in the Brain After Permanent Middle Cerebral Artery Occlusion

There were a total of ∼15,000 leukocytes present in the ischemic hemisphere at both 3and 24 hours after pMCAO, which was 3- to 5-fold more than in the contralateral (nonischemic) hemisphere or in sham controls (Figures 1A and 4). Of these, lymphoid cells (CD11b−) represented 30% to 40%, whereas myeloid cells (CD11b+) represented 60% to 70% (Figure 1) of total leukocytes.

Figure 1.

Figure 1

Open in a new tab

Flow cytometric quantification of leukocytes in the brain, expressed as total, myeloid, or lymphoid cells, at 3 or 24 hours after permanent middle cerebral artery occlusion (pMCAO) (A), or at 24 hours after 1- or 2-hour transient middle cerebral artery occlusion (tMCAO) (B). Data are shown for the contralateral and ischemic hemispheres, and compared with data from naïve or time-matched sham control animals. (n=5 to 10; *P<0.05 versus sham; #P<0.05 versus contralateral; one-way analysis of variance (ANOVA) with Bonferroni post tests). Microglia numbers are also shown after pMCAO (C) and tMCAO (D) (n=5 to 10; *P<0.05 versus sham; #P<0.05 versus contralateral; one-way ANOVA with Bonferroni post test). Data are mean±s.e.m.

Myeloid cells (CD11b+) were increased by ∼4-fold in the ischemic brain at 3 and 24 hours after pMCAO (Figure 1A). Neutrophils (Ly6G+) comprised >70% of myeloid cells (and up to 60% of all infiltrating leukocytes) after pMCAO, with ∼5,000 cells at 3 hours and ∼9,000 cells at 24 hours (Figures 2A and 4). A 2- to 4-fold increase in macrophages and monocytes (F4/80+ or Ly6C+, respectively) was observed at both 3 and 24 hours (Figures 2D and 2E). Dendritic cells (CD11b+CD11c+) were not increased at 3 hours but were ∼6-fold more numerous at 24 hours (Figure 2F). Numbers of resident brain microglia (CD45+medCD11b+F4/80+) tended to be increased ∼2-fold after pMCAO (Figure 1C).

Figure 2.

Figure 2

Open in a new tab

Quantification of leukocyte subtypes in brain at 3 or 24 hours after permanent middle cerebral artery occlusion, compared with naïve and time-matched sham controls (n=5 to 10, *P<0.05; one-way analysis of variance (ANOVA) with Bonferroni post tests). Data are shown for neutrophils (A), T cells (B), B cells (C), macrophages (D), monocytes (E), dendritic cells (F), CD4+ T cells (G), CD4+CD25+ T cells (H), CD8+ T cells (I), natural killer (NK) cells (J), natural killer T (NKT) cells (K), and CD4−CD8− T cells (L), and expressed as mean±s.e.m.

Lymphoid cells were increased by ∼2-fold at 3 and 24 hours after pMCAO (Figure 1A). B cells (B220+) were increased by 3- to 4-fold (Figure 2C). T lymphocytes (CD3+) were increased by 2- to 3-fold at 3 and 24 hours (Figure 2B). Of these, CD4+ T cells had not increased significantly by 3 hours, but were 4- to 5-fold more numerous at 24 hours (Figure 2G). CD4+CD25+ T cells comprised ∼30% of CD4+ cells, and followed the same profile as total CD4+ cells (Figure 2H). By contrast, CD8+ T cells were increased by 3- to 4-fold at 3 and 24 hours (Figure 2I). NK cells (NK1.1+CD3−; Figure 2J) and CD8−CD4− T cells (i.e., also CD3+; Figure 2L) followed by a similar profile to CD8+ cells, whereas NKT cells (NK1.1+CD3+) were more like CD4+ cells in that their numbers were not increased until 24 hours after pMCAO (Figure 2K).

Immune Cell Numbers in the Brain After Transient Middle Cerebral Artery Occlusion

There were ∼8,000 leukocytes (CD45+high cells) present in the ischemic hemisphere at 24 hours after either 1 or 2 hours of tMCAO, which was 2- to 3-fold more than in the contralateral (nonischemic) hemisphere or in sham controls (Figure 1B). Of these, lymphoid cells (CD11b−) and myeloid cells (CD11b+) each represented ∼50% of total leukocytes (Figures 1B and 4). Fewer leukocytes in brains after tMCAO versus pMCAO was largely due to lower numbers of myeloid cells (Figures 1A and 1B).

Myeloid cells (CD11b+) were increased in the ischemic brain by ∼3-fold at 24 hours after tMCAO (Figure 1B). Neutrophils (Ly6G+) were increased by 5- to 6-fold at 24 hours (Figure 3A) and comprised ∼60% of myeloid cells (and ∼40% of all infiltrating leukocytes) after tMCAO (Figures 3A and 4). An ∼3-fold increase in macrophages and monocytes (F4/80+ or Ly6C+, respectively) was observed at 24 hours after tMCAO (Figures 3D and 3E). Dendritic cells (CD11b+CD11c+) tended to increase by >10-fold at 24 hours tMCAO (Figure 3F), but represented only ∼2% of all infiltrating leukocytes (Figure 4). Numbers of resident brain microglia (CD45+medCD11b+F4/80+) increased by 3- to 4-fold after tMCAO in both ischemic and contralateral hemispheres (Figure 1D).

Figure 3.

Figure 3

Open in a new tab

Quantification of leukocyte subtypes in brain at 24 hours after transient middle cerebral artery occlusion, compared with naïve and time-matched sham controls (n=5, *P<0.05; one-way analysis of variance (ANOVA) with Bonferroni post tests). Data are shown for neutrophils (A), T cells (B), B cells (C), macrophages (D), monocytes (E), dendritic cells (F), CD4+ T cells (G), CD4+CD25+ T cells (H), CD8+ T cells (I), natural killer (NK) cells (J), natural killer T (NKT) cells (K), and CD4−CD8− T cells (L), and expressed as mean±s.e.m.

Figure 4.

Figure 4

Open in a new tab

Pie charts summarizing number and composition of immune cells in ischemic hemispheres of mouse brains at 3 hours (A) or 24 hours (B) after permanent middle cerebral artery occlusion (pMCAO) or at 24 hours after 1 hour of transient middle cerebral artery occlusion (tMCAO) (C), and of brain hemispheres from naïve (D) or time-matched sham (E–G) control mice. The area of each pie is proportional to the number of leukocytes per hemisphere (also shown as mean±s.e.m.). n=20 for naïve; n=10 to 15 for all other groups.

Lymphoid cells were increased by 2- to 3-fold at 24 hours after tMCAO (Figure 1B). Approximately 40% of these were B cells (B220+; Figures 3C and 4), which were increased by ∼2-fold (Figure 3C). T cells (CD3+) were increased by 3- to 5-fold at 24 hours (Figure 3B). Of these, CD4+ T cells were ∼4-fold more numerous (Figure 3G). CD4+CD25+ cells comprised >50% of CD4+ cells, and followed the same profile as total CD4+ cells (Figure 3H). CD8+ T cells and CD8−CD4− T cells were also increased by 3-fold at 24-hour tMCAO (Figures 3I and 3L). NK cells (NK1.1+CD3−; Figure 3J) were increased by ∼2-fold whereas NKT cells (NK1.1+CD3+) were increased by ∼4-fold at 24 hours after pMCAO (Figure 3K).

Immune Cell Numbers in Blood and Spleen After Permanent Middle Cerebral Artery Occlusion

No significant changes in the number of any circulating immune cells were found at 3 hours after pMCAO. However, at 24 hours after pMCAO the proportion of leukocytes that were neutrophils increased by ∼3-fold. By contrast, lymphoid cells were reduced from ∼80% to ∼30% of total leukocytes at 24 hours after pMCAO (Supplementary Figure 3). No changes were observed in numbers of any immune cells in spleen at either 3 or 24 hours after pMCAO (Supplementary Figure 4). Similarly, spleen weights were not significantly different at 3 hours (103.2±8.5 mg) or at 24 hours (82.2±5.7 mg) after pMCAO, compared with time-matched sham controls (89.5±3.8 mg and 75.2±5.1 mg, respectively; P>0.05).

Localization of Leukocytes After Permanent Middle Cerebral Artery Occlusion

We utilized immunohistochemistry, via an anti-MPO antibody, to localize neutrophils—the most prominent type of infiltrating leukocyte—in relation to the infarcted region within 3 hours after pMCAO (Figures 5 and 6A). It is possible that some more weakly stained MPO+ cells were instead macrophages. Cell density of MPO+ was markedly higher (∼7-fold; Figure 5) in the infarct compared with noninfarct regions from the ischemic hemisphere or the contralateral hemisphere. Myeloperoxidase cells appeared to be evenly distributed within the infarct, with no notable difference between infarct border areas (within 1 mm from the infarct border), and remote areas (>1 mm within the infarct border) (Figure 5). Most of the infiltrating leukocytes within the infarct were found to be present outside the vasculature (Figure 6). There was no evidence of hemorrhagic transformation (e.g., areas of erythrocytes in the parenchyma) in any of the brain sections examined after pMCAO.

Figure 5.

Figure 5

Open in a new tab

Representative photomicrographs showing localization of myeloperoxidase (MPO+) cells in mouse brain at 3 hour after permanent middle cerebral artery occlusion (pMCAO). (A) Low magnification of a thionin-stained section that outlines the infarct area (lighter in color; border shown as dashed line). (B) The perilesional area from the ischemic hemisphere of a thionin-stained coronal brain section, as observed under × 100 magnification. (C) A consecutive section was stained with anti-MPO antibody and examined under the same magnification; brown spots indicate MPO+ cells. The majority of MPO+ cells were present within the infarct. (D) Granule-containing MPO+ cells (indicated by arrows) were observed under further magnification ( × 400). Scale bars in (B–D)=100 μm. (E) Quantification of MPO+ cell density in the contralateral hemisphere, noninfarcted areas of the ischemic hemisphere, and infarcted areas (either within 1 mm of the infarct border or deeper in the infarct core >1 mm from infarct border). *P<0.05 compared with contralateral hemisphere; #P<0.05 compared with noninfarcted area. n=a total of 128 high power fields of brain sections from 4 mice, one-way analysis of variance (ANOVA), with Bonferroni post tests. Data are mean±s.e.m.

Figure 6.

Figure 6

Open in a new tab

Neutrophils, T cells, and macrophages are infiltrated into the ischemic infarct at 3 hours after permanent middle cerebral artery occlusion (pMCAO). Representative overlayed images of myeloperoxidase (MPO+) cells (A), CD3+ cells (B), or F4/80+ cells (C) (red fluorescence) with endothelial marker von Willebrand Factor (vWF; green fluorescence) show that most immune cells are located outside the vasculature. Scale bar=50 μm.

Effect of Flushing with Phosphate-Buffered Saline Before Brain Removal

Consistent with the immunohistochemical data in Figure 6, the quantity of infiltrating leukocytes remaining within in the 24-hour pMCAO brain, as estimated by flow cytometry, was reduced by only ∼10% to 20% by flushing the brain with saline before removal (n=5 each, P>0.05 versus unflushed; Supplementary Figure 5).

Transient Effect of Sham Surgery on Number of Intravascular Leukocytes

We noted that sham surgery appeared to cause a small, transient increase in leukocyte numbers in the brain at 3 hours but which had disappeared by 24 hour (see Figures 4D–4G). To explore whether these cells might be present in the intravascular space, we performed a further 12 experiments using flow cytometry in either naïve or saline-flushed versus nonflushed brains from sham-operated mice taken 3 hours after surgery. The data indicate that the increased leukocyte numbers can be accounted for by a greater presence of neutrophils, and this can be reduced by saline flushing (Supplementary Figure 6).

Discussion

Inflammation appears to have an important role in the brain injury that results from cerebral ischemia.13, 18 It has been assumed that the process of postischemic brain inflammation is facilitated by reperfusion but is limited in the absence of reperfusion. Our study has examined the profile of immune cell infiltration at early time points after pMCAO in mice, a model of human MCA infarction lacking cerebral reperfusion. We discovered that marked leukocyte infiltration occurs in the brain within 3 hours after pMCAO and is maintained for at least 24 hours. Specifically, infiltrating leukocyte populations that are already present in the ischemic hemisphere in stable numbers as early as 3 hours include neutrophils in particular, but also CD8+ T cells, B cells, NK cells, monocytes, and macrophages. Infiltration of CD4+ T cells, NKT cells, and dendritic cells is slower, and occurs later than 3 hours. We hypothesized that brain infiltration of leukocytes after cerebral ischemia would be substantially greater after tMCAO in comparison with pMCAO, due to the augmented brain perfusion occurring after removing a temporary (1 or 2 hours) occlusion of the MCA. Surprisingly, we found that over 24 hours after tMCAO, numbers of most leukocyte populations infiltrating the ischemic brain were less than those seen after pMCAO, including substantially fewer (∼50%) neutrophils.

We found that neutrophils were the most numerous cell type (representing approximately one half) infiltrating the brain throughout the first 24 hours after pMCAO, most of which were present within 3 hours of pMCAO. Previous studies of experimental stroke in rats using histochemical approaches identified neutrophils to be one of the earliest cell types infiltrating the ischemic brain, contributing to inflammation as early as 12 hours after pMCAO.19 Furthermore, pharmacological inhibition (at 1.5 hours) or genetic deletion of neutrophil elastase was reported to reduce infarct volume in mice after tMCAO but not pMCAO, suggesting that reperfusion may be necessary to allow neutrophils to access and elicit damage to vulnerable ischemic tissue.20 However, here our comprehensive analyses of whole ischemic hemispheres utilising flow cytometry have revealed that neutrophils are ∼3-fold as numerous in the ischemic hemisphere at 24 hours after pMCAO compared with 1 or 2 hours of tMCAO, despite a comparable infarct volume after 2-hour tMCAO and the pMCAO models. Further histochemical analysis indicated that leukocytes, particularly neutrophils, T cells, and macrophages, were mostly present within the parenchyma of the infarcted zone after pMCAO. This indicates that neutrophil infiltration readily occurs throughout the infarcted tissue after cerebral ischemia and is apparently not dependent on blood perfusion being restored. Studies in poststroke human brain have also suggested that neutrophil accumulation is positively correlated with severity of lesion and neurologic deficit9 or rate of infarct expansion.21 Given that in the present study, continuing occlusion of the MCA was evidently no barrier to the effective infiltration of the ischemic tissue by neutrophils over 24 hours, and that pMCAO in our model generates an infarct that is ∼2-fold larger than 1 hour of tMCAO,14 it seemed to be plausible that the degree of neutrophil infiltration into the ischemic hemisphere was quantitatively dependent on the infarct volume of each model. However, our additional studies after 2 hours of tMCAO plus 22 hours of reperfusion indicated that numbers of infiltrating leukocytes were not strictly related to infarct volume but were perhaps more related to whether reperfusion occurred. Surprisingly, reperfusion resulted in a markedly lower number of immune cells infiltrating the parenchyma. This may suggest that the severity of ongoing hypoxia in the infarct core, and not simply the size of the infarct, is a major stimulus for recruitment and retainment of immune cells in the brain after stroke.

Whether neutrophil accumulation causes secondary brain damage, and can be effectively blocked, after cerebral ischemia in animals and/or humans remains controversial. In addition to the findings of Stowe et al20 that neutrophil elastase exerts poststroke injury in the brain, Chopp et al22, 23 found that a neutrophil inhibitory factor (UK-279,276) reduced infarct volume in rats when administered continuously from 2 to 4 hours after tMCAO for up to a week. However, when administered within 6 hours of symptom onset, UK-279,276 was found not to improve overall recovery in a study of 966 acute ischemic stroke patients regardless of whether they received t-PA.24 We reported that daily administration of a CXCR2 antagonist, commencing at the beginning of reperfusion after 0.5 hour tMCAO in mice, blocked MPO+ cell infiltration but did not alter survival rate, neurologic deficit, or infarct volume over 72 hours.11 Considering our present finding that there is profound and virtually maximal neutrophil infiltration from at least as early as 3 hours, and sustained for at least 24 hours after cerebral ischemia even without reperfusion, it may not be feasible or realistic to intervene early enough (e.g., within 1.5 hours as in Stowe et al) to prevent infiltration and damage by neutrophils in acute stroke patients.

We observed increased numbers of monocytes and macrophages in the ischemic hemisphere after pMCAO, both of which had increased substantially by 3 hours. Monocytes were ∼2-fold more prevalent at 24 hours after pMCAO compared with tMCAO, whereas the opposite trend was true for macrophages. Denes et al25 reported that degeneration of microglia occurred in the ischemic core after prolonged cerebral ischemia, and noted that more severe ischemic injury was associated with low microglial numbers and an impaired proliferative response. Those findings are in accord with our results, in that generally the severity of ischemia (i.e., 24-hour pMCAO>3-hour pMCAO>2-hour tMCAO+22-hour reperfusion>1-hour tMCAO+23-hour reperfusion) was negatively correlated with the number of microglia observed. Interestingly, in both models of ischemia, increases in microglia occurred bilaterally rather than being confined to the ischemic hemisphere, as was typical for other cell types. In addition to our flow cytometry data that quantified microglia in brain homogenates as CD45+medCD11b+F4/80+ cells, we confirmed that a similar profile was observed for Iba+ cells in brain sections (data not shown).

We found a substantial increase in T lymphocytes in the ischemic hemisphere as early as 3 hours after pMCAO, which is earlier than most others have reported to occur after tMCAO.8, 14 Moreover, a differential temporal profile was observed among subpopulations of T cells. CD8+ cells were markedly increased by 3 hours and tended to be less numerous at 24 hours after pMCAO. Numbers of CD4−CD8− T cells, which are involved in the downregulation of immune responses,26 were similar to those of CD8+ cells in both models. By contrast, CD4+ cells were not significantly increased until 24 hours after pMCAO. Similar numbers of both CD8+ and CD4+ cells were present at 24 hours in the two models. Infiltrating NKT cells displayed a similar temporal profile as CD4+ T cells in both models, but were only ∼10% as numerous. Natural killer T cells recognize self and foreign lipid antigens presented by CD1d, including bacterial glycolipids, and are reported to have important roles in mechanisms of immune modulation after stroke, especially in stroke-induced immunosuppression.27, 28 T lymphocytes have previously been reported to be present in postischemic brain tissue by 24 hours after tMCAO,8, 14 and there is evidence that both CD8+ and CD4+ T cells contribute to postischemic injury in mice.29 CD4+CD25+Forkhead box P3+(FoxP3+) regulatory T (Treg) cells have been reported to have a protective, immunomodulatory role in the brain over several days after stroke,30, 31 but a detrimental role during more acute conditions.32 We found no increase in CD4+CD25+ T cells, which includes activated CD4+ T cells and Tregs, at 3 hours after pMCAO, but a marked increase in these cells in the ischemic hemisphere 24 hours after either pMCAO or tMCAO. A 10-fold increase in Treg cells was recently reported at 14 days after tMCAO.33

We found that numbers of B cells were increased by 2- to 3-fold over sham levels at 24 hours after either pMCAO or tMCAO, and these cells were even more numerous earlier at 3 hours after pMCAO. B cells can function as antigen-presenting cells to activate cytotoxic (CD8+) T cells, but there is recent data to suggest that a regulatory B-cell subpopulation may modulate outcome in experimental stroke. B cell-deficient mice had larger infarct volumes, higher mortality and an increased number of activated T cells, macrophages, microglia, and neutrophils, compared with wild-type control mice after tMCAO.16, 34 IL-10-secreting regulatory B cells have been identified as a major regulatory B-cell subtype,16, 34 however, little is known about the initial temporal profile of B-cell infiltration in the brain after ischemia. Previous flow cytometric studies have identified increases in B cells at 3 days after 0.5 hour tMCAO8 and 5 days after pMCAO by electrocoagulation.35 Clarification of the functions of different B-cell subtypes will be important for the possible development of B cell-related therapies for acute stroke.

We observed an ∼4-fold increase in dendritic cells at 24 hours after pMCAO. A previous immunohistochemical study reported increased levels of dendritic cells in the ischemic lesion after pMCAO.36 Dendritic cells have also been shown to be increased until day 6, predominantly around the infarcted brain tissue after photochemically induced focal ischemia in mice.37 Dendritic cells are involved in antigen presentation during immune cell activation. They can also induce self-tolerance via release of different cytokines, which have an important role in adaptive responses of immune regulation.38 The precise role(s) of dendritic cells in outcome after cerebral ischemia is yet to be established.

We found that at 3 hours after sham surgery, the number of total leukocytes, especially neutrophils, were more numerous in the brain than at 24 hours after sham surgery (see Figures 4E–4G). Flow cytometry data indicated that these increased leukocyte numbers could be reduced by saline flushing. This suggests that general anesthesia with ketamine/xylazine may result in a mild and temporary neutrophil-related inflammation within the cerebral vasculature of mice.

Overall, we have described the infiltration profile of several leukocyte subtypes during the first 24 hours after pMCAO—a model of human malignant MCA infarction—as well as at 24 hours after tMCAO in mice. One limitation of the study could be that the brains were not flushed with saline before tissue collection, so that the data do not strictly exclude cells remaining in the vasculature and not extravasated. However, we do not believe that such a phenomenon contributed significantly to the interpretation of our data because: (1) in a subset of experiments we found using flow cytometry that flushing had only a modest effect on the number of CD45+ cells present in the ischemic hemisphere and (2) immunohistochemical analyses of unflushed brains indicated that most infiltrating leukocytes had extravasated and were localized outside blood vessels and extensively dispersed throughout the infarcted tissue. Moreover, we chose to focus on data from unflushed brains since any such leukocytes adherent to the cerebral endothelium after stroke are likely to be relevant to postischemic brain inflammatory mechanisms and are therefore appropriate to be included in any quantitation of cell numbers. Finally, we cannot exclude the possibility that increased expression of CD45, together with CD11c or F4/80, by microglia after stroke was in part falsely ascribed to dendritic cells or macrophages, respectively.

In summary, these comparative data describing the infiltration profiles of numerous leukocyte subtypes into the postischemic brain in the absence or presence of reperfusion should assist in our understanding of early inflammatory changes in brain after ischemic stroke. Our data are particularly relevant for the severe setting of malignant MCA infarction, where we found a surprisingly large degree of leukocyte infiltration to occur very early after focal ischemia in the absence of reperfusion. So far, no established medical therapies for malignant MCA infarction have reached clinical practice. The major clinical problem in malignant MCA infarction is the development of massive brain edema, which then leads to increased intracranial pressure and subsequently evolving secondary tissue damage. Due to the lack of pharmacological strategies, decompressive surgery of the rapidly evolving brain edema has been proposed for patients with space-occupying hemispheric infarction.39 Inflammatory mechanisms are well accepted to contribute to the development of brain edema in ischemic tissue damage.40 Our observation of massive immune cell infiltration in the setting of permanent brain ischemia suggests that pharmacological strategies targeting inflammatory mechanisms might be a more promising therapeutic option than expected to reduce brain edema in patients with malignant MCA infarction. These new medical treatments could be applied in combination with established surgical approaches. Future studies should evaluate therapies to interfere with leukocyte infiltration early after stroke, regardless of whether reperfusion is possible.

The authors declare no conflict of interest.

Footnotes

Supplementary Information accompanies the paper on the Journal of Cerebral Blood Flow & Metabolism website (http://www.nature.com/jcbfm)

Supplementary Material

Supplementary Information
Click here for additional data file. (3.4MB, doc)

References

  1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–e220. doi: 10.1161/CIR.0b013e31823ac046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP., Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945–2948. doi: 10.1161/STROKEAHA.109.192535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Frank JI. Large hemispheric infarction, deterioration, and intracranial pressure. Neurology. 1995;45:1286–1290. doi: 10.1212/wnl.45.7.1286. [DOI] [PubMed] [Google Scholar]
  4. Berrouschot J, Sterker M, Bettin S, Koster J, Schneider D. Mortality of space-occupying ('malignant') middle cerebral artery infarction under conservative intensive care. Intensive Care Med. 1998;24:620–623. doi: 10.1007/s001340050625. [DOI] [PubMed] [Google Scholar]
  5. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996;53:309–315. doi: 10.1001/archneur.1996.00550040037012. [DOI] [PubMed] [Google Scholar]
  6. Sacco RL. Risk factors and outcomes for ischemic stroke. Neurology. 1995;45:S10–S14. [PubMed] [Google Scholar]
  7. McKenna A, Wilson CF, Caldwell SB, Curran D. Functional outcomes of decompressive hemicraniectomy following malignant middle cerebral artery infarctions: a systematic review. Br J Neurosurg. 2012;26:310–315. doi: 10.3109/02688697.2012.654835. [DOI] [PubMed] [Google Scholar]
  8. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009;40:1849–1857. doi: 10.1161/STROKEAHA.108.534503. [DOI] [PubMed] [Google Scholar]
  9. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke. 1996;27:1739–1743. doi: 10.1161/01.str.27.10.1739. [DOI] [PubMed] [Google Scholar]
  10. Weston RM, Jones NM, Jarrott B, Callaway JK. Inflammatory cell infiltration after endothelin-1-induced cerebral ischemia: histochemical and myeloperoxidase correlation with temporal changes in brain injury. J Cereb Blood Flow Metab. 2007;27:100–114. doi: 10.1038/sj.jcbfm.9600324. [DOI] [PubMed] [Google Scholar]
  11. Brait VH, Rivera J, Broughton BR, Lee S, Drummond GR, Sobey CG. Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome. Brain Res. 2011;1372:169–179. doi: 10.1016/j.brainres.2010.11.087. [DOI] [PubMed] [Google Scholar]
  12. Emerich DF, Dean RL, 3rd, Bartus RT. The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct. Exp Neurol. 2002;173:168–181. doi: 10.1006/exnr.2001.7835. [DOI] [PubMed] [Google Scholar]
  13. Brait VH, Arumugam TV, Drummond GR, Sobey CG. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. J Cereb Blood Flow Metab. 2012;32:598–611. doi: 10.1038/jcbfm.2012.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Brait VH, Jackman KA, Walduck AK, Selemidis S, Diep H, Mast AE, et al. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab. 2010;30:1306–1317. doi: 10.1038/jcbfm.2010.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006;113:2105–2112. doi: 10.1161/CIRCULATIONAHA.105.593046. [DOI] [PubMed] [Google Scholar]
  16. Ren X, Akiyoshi K, Dziennis S, Vandenbark AA, Herson PS, Hurn PD, et al. Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci. 2011;31:8556–8563. doi: 10.1523/JNEUROSCI.1623-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412. doi: 10.1371/journal.pbio.1000412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nat Rev Neurol. 2012;8:401–410. doi: 10.1038/nrneurol.2012.98. [DOI] [PubMed] [Google Scholar]
  19. Barone FC, Hillegass LM, Tzimas MN, Schmidt DB, Foley JJ, White RF, et al. Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke. Mol Chem Neuropathol. 1995;24:13–30. doi: 10.1007/BF03160109. [DOI] [PubMed] [Google Scholar]
  20. Stowe AM, Adair-Kirk TL, Gonzales ER, Perez RS, Shah AR, Park TS, et al. Neutrophil elastase and neurovascular injury following focal stroke and reperfusion. Neurobiol Dis. 2009;35:82–90. doi: 10.1016/j.nbd.2009.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Price CJ, Menon DK, Peters AM, Ballinger JR, Barber RW, Balan KK, et al. Cerebral neutrophil recruitment, histology, and outcome in acute ischemic stroke: an imaging-based study. Stroke. 2004;35:1659–1664. doi: 10.1161/01.STR.0000130592.71028.92. [DOI] [PubMed] [Google Scholar]
  22. Jiang N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res. 1998;788:25–34. doi: 10.1016/s0006-8993(97)01503-5. [DOI] [PubMed] [Google Scholar]
  23. Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M, Chopp M. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke. 2003;34:1790–1795. doi: 10.1161/01.STR.0000077016.55891.2E. [DOI] [PubMed] [Google Scholar]
  24. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34:2543–2548. doi: 10.1161/01.STR.0000092527.33910.89. [DOI] [PubMed] [Google Scholar]
  25. Denes A, Vidyasagar R, Feng J, Narvainen J, McColl BW, Kauppinen RA, et al. Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab. 2007;27:1941–1953. doi: 10.1038/sj.jcbfm.9600495. [DOI] [PubMed] [Google Scholar]
  26. McIver Z, Serio B, Dunbar A, O'Keefe CL, Powers J, Wlodarski M, et al. Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2008;141:170–178. doi: 10.1111/j.1365-2141.2008.07021.x. [DOI] [PubMed] [Google Scholar]
  27. Wong CH, Jenne CN, Lee WY, Leger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science. 2011;334:101–105. doi: 10.1126/science.1210301. [DOI] [PubMed] [Google Scholar]
  28. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. 2013;13:101–117. doi: 10.1038/nri3369. [DOI] [PubMed] [Google Scholar]
  29. Liesz A, Zhou W, Mracsko E, Karcher S, Bauer H, Schwarting S, et al. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain. 2011;134:704–720. doi: 10.1093/brain/awr008. [DOI] [PubMed] [Google Scholar]
  30. Gobel K, Bittner S, Melzer N, Pankratz S, Dreykluft A, Schuhmann MK, et al. CD4(+) CD25(+) FoxP3(+) regulatory T cells suppress cytotoxicity of CD8(+) effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level. J Neuroinflammation. 2012;9:41. doi: 10.1186/1742-2094-9-41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15:192–199. doi: 10.1038/nm.1927. [DOI] [PubMed] [Google Scholar]
  32. Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Gobel K, Schuhmann MK, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood. 2013;121:679–691. doi: 10.1182/blood-2012-04-426734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Stubbe T, Ebner F, Richter D, Engel O, Klehmet J, Royl G, et al. Regulatory T cells accumulate and proliferate in the ischemic hemisphere for up to 30 days after MCAO. J Cereb Blood Flow Metab. 2012;33:37–47. doi: 10.1038/jcbfm.2012.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Offner H, Hurn PD. A Novel Hypothesis: Regulatory B Lymphocytes Shape Outcome from Experimental Stroke. Transl Stroke Res. 2012;3:324–330. doi: 10.1007/s12975-012-0187-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Zhou W, Liesz A, Bauer H, Sommer C, Lahrmann B, Valous N, et al. Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models. Brain Pathol. 2013;23:34–44. doi: 10.1111/j.1750-3639.2012.00614.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Kostulas N, Li HL, Xiao BG, Huang YM, Kostulas V, Link H. Dendritic cells are present in ischemic brain after permanent middle cerebral artery occlusion in the rat. Stroke. 2002;33:1129–1134. doi: 10.1161/hs0402.105379. [DOI] [PubMed] [Google Scholar]
  37. Reichmann G, Schroeter M, Jander S, Fischer HG. Dendritic cells and dendritic-like microglia in focal cortical ischemia of the mouse brain. J Neuroimmunol. 2002;129:125–132. doi: 10.1016/s0165-5728(02)00184-4. [DOI] [PubMed] [Google Scholar]
  38. Steptoe RJ, Thomson AW. Dendritic cells and tolerance induction. Clin Exp Immunol. 1996;105:397–402. doi: 10.1046/j.1365-2249.1996.d01-779.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Juttler E, Schwab S, Schmiedek P, Unterberg A, Hennerici M, Woitzik J, et al. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke. 2007;38:2518–2525. doi: 10.1161/STROKEAHA.107.485649. [DOI] [PubMed] [Google Scholar]
  40. Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis. 2008;32:200–219. doi: 10.1016/j.nbd.2008.08.005. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
Click here for additional data file. (3.4MB, doc)

Articles from Journal of Cerebral Blood Flow & Metabolism are provided here courtesy of SAGE Publications

RESOURCES